SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in reducing the risk of atrial fibrillation (AF). However, the results are controversial and the underlying metabolic mechanism remains unclear. Emerging evidence implied that SGLT2 inhibitors have extra beneficial meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiang, Yu, Yuefeng, Sun, Ying, Yu, Bowei, Tan, Xiao, Wang, Bin, Lu, Yingli, Wang, Ningjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583416/
https://www.ncbi.nlm.nih.gov/pubmed/37848934
http://dx.doi.org/10.1186/s12933-023-02019-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583416/
https://www.ncbi.nlm.nih.gov/pubmed/37848934
http://dx.doi.org/10.1186/s12933-023-02019-8

Ejemplares similares